Pet Vivo Holdings, Inc. PETV
We take great care to ensure that the data presented and summarized in this overview for PetVivo Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PETV
Top Purchases
Top Sells
About PETV
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
Insider Transactions at PETV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 29
2025
|
John Lai Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
206,839
+9.65%
|
$0
$0.76 P/Share
|
|
Jul 29
2025
|
Garry N Lowenthal Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
68,276
+11.73%
|
$0
$0.76 P/Share
|
|
Jul 01
2025
|
Michael Eugene Eldred Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,372
+12.6%
|
$0
$0.78 P/Share
|
|
May 19
2025
|
Garry N Lowenthal Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
29,412
+6.2%
|
$0
$0.51 P/Share
|
|
Apr 14
2025
|
Garry N Lowenthal Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
75,000
+15.28%
|
$0
$0.5 P/Share
|
|
Apr 14
2025
|
John Lai Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
100,000
+5.47%
|
$0
$0.5 P/Share
|
|
Mar 31
2025
|
Robert J Costantino Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,458
+21.2%
|
-
|
|
Mar 31
2025
|
John Spencer Breithaupt Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,687
+21.01%
|
$0
$0.6 P/Share
|
|
Mar 31
2025
|
Robert James Rudelius Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,589
+4.91%
|
$0
$0.6 P/Share
|
|
Mar 31
2025
|
Joseph William Jasper Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,905
+9.11%
|
$0
$0.6 P/Share
|
|
Mar 31
2025
|
Diane M Levitan Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,989
+16.97%
|
-
|
|
Feb 28
2025
|
Michael Eugene Eldred Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+14.81%
|
$0
$0.54 P/Share
|
|
Jan 14
2025
|
John Lai Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
225,000
+12.54%
|
-
|
|
Dec 18
2024
|
John Lai Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
60,904
+3.6%
|
$0
$0.41 P/Share
|
|
Dec 18
2024
|
Garry N Lowenthal Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
60,904
+15.16%
|
$0
$0.41 P/Share
|
|
Dec 16
2024
|
Garry N Lowenthal Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
100,000
+26.32%
|
$0
$0.41 P/Share
|
|
Dec 01
2024
|
Michael Eugene Eldred Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+38.71%
|
$0
$0.5 P/Share
|
|
Oct 30
2024
|
Robert James Rudelius Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+25.89%
|
$0
$0.5 P/Share
|
|
Oct 16
2024
|
Robert James Rudelius Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+15.82%
|
-
|
|
Oct 16
2024
|
John Spencer Breithaupt Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.74M shares |
|---|